Next Article in Journal / Special Issue
Number of Axillary Lymph Node Metastases Determined by Preoperative Ultrasound is Related to Prognosis in Patients with Breast Cancer
Previous Article in Journal
N′1,N′3-Dimethyl-N′1,N′3-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS)
Previous Article in Special Issue
Comparison of Locoregional Recurrence with Mastectomy vs. Breast Conserving Surgery in Pregnancy Associated Breast Cancer (PABC)
Article Menu

Export Article

Open AccessReview
Cancers 2010, 2(1), 1-19; doi:10.3390/cancers2010001

Novel Combinations for the Treatment of Metastatic Breast Cancer

Weill Cornell Medical College, 425 East 61st Street, 8th Floor, New York, NY 10065, USA
Received: 17 November 2009 / Revised: 29 December 2009 / Accepted: 5 January 2010 / Published: 14 January 2010
(This article belongs to the Special Issue Breast Cancer)
View Full-Text   |   Download PDF [526 KB, uploaded 14 January 2010]

Abstract

Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixabepilone is the only chemotherapy combination specifically approved for MBC after failure of anthracyclines and taxanes. Other options have limited data to support their use in this setting but are commonly used in practice. Future MBC therapies will likely combine alternative chemotherapies and novel biologic agents, and numerous ongoing trials should help to further define the proper use of these regimens. View Full-Text
Keywords: metastatic breast cancer; anthracycline failure; taxane failure; combination therapy; chemotherapy; targeted or biologic therapy; outcomes; survival metastatic breast cancer; anthracycline failure; taxane failure; combination therapy; chemotherapy; targeted or biologic therapy; outcomes; survival
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Vahdat, L.T. Novel Combinations for the Treatment of Metastatic Breast Cancer. Cancers 2010, 2, 1-19.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top